We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Fusion Health Care, a pharma company based at Hyderabad, has announced the launch of its favipiravir drug under the brand name XARAVIR, for the treatment of mild to moderate COVID-19 cases.